Caenorhabditis elegans is an instrumental analysis mannequin used to advance our data in areas together with growth, metabolism, and getting old. However, analysis on metabolism and/or different measures of well being/getting old are confounded by the nematode’s food source in the lab, reside E. coli micro organism. Commonly used therapies, together with ultraviolet irradiation and antibiotics, are profitable in stopping bacterial replication, however the micro organism can stay metabolically energetic. The goal of this examine is to develop a metabolically inactive food source for the worms that may enable us to attenuate the confounding results of bacterial metabolism on worm metabolism and getting old.
Our technique is to make use of a paraformaldehyde (PFA) handled E. coli food source and to find out its results on worm well being, metabolism and longevity. We initially decide the bottom potential concentrations of PFA essential to quickly and reproducibly kill micro organism. We then measure numerous points of worm conduct, well beingspan and longevity, together with progress price, food attraction, brood measurement, lifespan and metabolic assessments, comparable to oxygen consumption and metabolomics. Our ensuing knowledge present that worms eat and develop effectively on these micro organism and assist the usage of 0.5% PFA-killed micro organism as a nematode food source for metabolic, drug, and longevity experiments.
Primary goal 1. To assess the consequences of offering grownup sufferers with entry to digital well being information (EHRs) alone or with extra functionalities on a variety of affected person, patient-provider, and well being useful resource consumption outcomes, together with affected person data and understanding, affected person empowerment, affected person adherence, affected person satisfaction with care, adversarial occasions, well being-related high quality of life, well being-related outcomes, psychosocial well being outcomes, well being useful resource consumption, and patient-provider communication. Secondary goal 1. To assess whether or not results of offering grownup sufferers with EHR entry alone versus EHR entry with extra functionalities differ amongst affected person teams in line with age, academic degree, or completely different standing of illness (power or acute).

Adult affected person entry to digital well being information
We included 10 studies with 78 to 4500 members and follow-up from three to 24 months. Nine studies assessed the consequences of EHR with extra functionalities, every addressing a subset of outcomes sought by this assessment. Five studies targeted on sufferers with diabetes mellitus, 4 on sufferers with particular ailments, and one on all sufferers. All studies in contrast EHR entry alone or with extra functionalities plus normal care versus normal care solely. No studies assessing the consequences of EHR entry alone versus EHR entry with extra functionalities had been recognized.
Interventions required a wide range of knowledge throughout the EHR, comparable to affected person historical past, drawback record, treatment, allergy symptoms, and lab outcomes. In addition to EHR entry, eight studies allowed sufferers to share self-documented knowledge, seven provided individualised illness administration features, seven provided academic disease-related info, six supported safe communication, and one provided preventive reminders. Only two studies had been at low or unclear threat of bias throughout domains. Meta-analysis couldn’t be carried out, as members, interventions, and outcomes had been too heterogeneous, and most studies introduced outcomes primarily based on completely different adjustment strategies or variables.
The high quality of proof was rated as low or very low throughout outcomes. Overall variations between intervention and management teams, if any, had been small. The relevance of any small results stays unclear for most outcomes as a result of in most instances, trial authors didn’t outline a minimal clinically essential distinction. Overall, outcomes recommend that the consequences of EHR entry alone and with extra functionalities are principally unsure compared with normal care. Patient data and understanding: very low-quality proof is offered from one examine, so we’re unsure about results of the intervention on affected person data about diabetes and blood glucose testing.
Patient empowerment: low-quality proof from three studies means that the intervention might have little or no impact on affected person empowerment measures. Patient adherence: low-quality proof from two studies means that the intervention might barely enhance adherence to the method of monitoring threat components and preventive providers. Effects on treatment adherence are conflicting in two studies; this will likely or might not enhance to a clinically related diploma. Patient satisfaction with care: low-quality proof from three studies means that the intervention might have little or no impact on affected person satisfaction, with conflicting outcomes.
Recombinant Mouse MIP-1 gamma (CCL9) |
|
MBS4159953-002mg |
MyBiosource |
0.02mg |
EUR 385 |
Recombinant Mouse MIP-1 gamma (CCL9) |
|
MBS4159953-1mg |
MyBiosource |
1(mg) |
EUR 4600 |
Recombinant Mouse MIP-1 gamma (CCL9) |
|
MBS4159953-5x1mg |
MyBiosource |
5x1mg |
EUR 20445 |
Recombinant Mouse MIP-1 gamma (CCL9) |
|
Z200375 |
ABM |
20 µg |
EUR 235 |
|
Description: Macrophage Inflammatory Protein-1 is a factor produced by macrophages that causes local inflammatory responses and induces superoxide production by neutrophils. Two peptides are responsible for this activity. They have been termed MIP-1-alpha, and MIP-1-beta. The two MIP proteins are the major factors produced by macrophages following their stimulation with bacterial endotoxins. Both proteins are involved in the cell activation of human granulocytes (neutrophils, eosinophils, and basophils) and appear to be involved in acute neutrophilic inflammation. Both forms of MIP-1 stimulate the production of reactive oxygen species in neutrophils and the release of lysosomal enzymes. They also induce the synthesis of other pro-inflammatory cytokines such as IL-1, IL-6 and TNF in fibroblasts and macrophages. MIP-1-alpha is a potent agonist of basophils, inducing a rapid change of cytosolic free calcium (see also: Calcium ionophore), the release of histamine and sulfido-leukotrienes, and chemotaxis. Murine MIP-1- alpha is the primary stimulator of TNF secretion by macrophages whereas MIP-1-beta antagonizes the inductive effects of MIP-1- alpha. In human monocytes the production of MIP-1-beta can be induced by bacterial lipopolysaccharides and IL-7. The biological activities of MIP-1-alpha and MIP-1-beta are mediated by receptors that bind both factors CCR5. A second species of receptors for these two factors also appears to bind MCAF. |
Recombinant Mouse MIP-1 gamma (CCL9) |
|
Z200379 |
ABM |
1.0 mg |
EUR 3900 |
|
Description: Macrophage Inflammatory Protein-1 is a factor produced by macrophages that causes local inflammatory responses and induces superoxide production by neutrophils. Two peptides are responsible for this activity. They have been termed MIP-1-alpha, and MIP-1-beta. The two MIP proteins are the major factors produced by macrophages following their stimulation with bacterial endotoxins. Both proteins are involved in the cell activation of human granulocytes (neutrophils, eosinophils, and basophils) and appear to be involved in acute neutrophilic inflammation. Both forms of MIP-1 stimulate the production of reactive oxygen species in neutrophils and the release of lysosomal enzymes. They also induce the synthesis of other pro-inflammatory cytokines such as IL-1, IL-6 and TNF in fibroblasts and macrophages. MIP-1-alpha is a potent agonist of basophils, inducing a rapid change of cytosolic free calcium (see also: Calcium ionophore), the release of histamine and sulfido-leukotrienes, and chemotaxis. Murine MIP-1- alpha is the primary stimulator of TNF secretion by macrophages whereas MIP-1-beta antagonizes the inductive effects of MIP-1- alpha. In human monocytes the production of MIP-1-beta can be induced by bacterial lipopolysaccharides and IL-7. The biological activities of MIP-1-alpha and MIP-1-beta are mediated by receptors that bind both factors CCR5. A second species of receptors for these two factors also appears to bind MCAF. |
Mouse MIP-1 gamma Recombinant Protein Lyophilized |
|
IMSMIP1GRLY5UG |
Innovative research |
each |
EUR 341 |
|
|
|
Description: Mouse MIP-1 gamma Recombinant Protein Lyophilized |
Mouse MIP-1 gamma Recombinant Protein Lyophilized |
|
MBS8434277-INQUIRE |
MyBiosource |
INQUIRE |
Ask for price |
Mouse MIP-1 gamma (CCL9/10) Recombinant Protein |
|
M10-036 |
ReliaTech |
20 µg |
EUR 196.35 |
|
Description: MIP-1γ is a CC chemokine found in murine blood and a wide variety of murine tissues, with no known human homolog. MIP-1γ signals through the CCR1 receptor. MIP-1γ chemoattracts neutrophils and also inhibits colony formation of bone marrow myeloid immature progenitors. MIP-1γ contains six cysteines including the four highly conserved cysteine residues present in CC chemokines. Recombinant murine MIP-1γ is an 11.6 kDa protein containing 101 amino acid residues. |
Mouse MIP-1 gamma (CCL9/10) Recombinant Protein |
|
M10-036S |
ReliaTech |
5 µg |
EUR 92.4 |
|
Description: MIP-1γ is a CC chemokine found in murine blood and a wide variety of murine tissues, with no known human homolog. MIP-1γ signals through the CCR1 receptor. MIP-1γ chemoattracts neutrophils and also inhibits colony formation of bone marrow myeloid immature progenitors. MIP-1γ contains six cysteines including the four highly conserved cysteine residues present in CC chemokines. Recombinant murine MIP-1γ is an 11.6 kDa protein containing 101 amino acid residues. |
Recombinant Mouse MIP-1 Gamma/CCL9/CCL10 protein |
|
CD00296-5ug |
Jiaxing Korain Biotech Ltd (BT Labs) |
5ug |
EUR 176 |
|
|
|
Description: Mouse CCL9/10 is belonging to the CC chemokine family. It is encoded by the gene CCL9. MRP-2 (CCL9/10) was isolated from a Mouse macrophage cell line, RAW 264.7. MRP-2 shows a 51 % sequence identity at the protein level to MRP-1 (C10) and 46% identity to MIP-1-alpha (CCL3). The functional receptor for CCL9/10 has been identified as CCR1. In contrast, other CCR1 ligands, CCL3/MIP-1alpha and CCL5/RANTES are considered to be primary CCR1 ligands in inflammatory responses. CCL9 can activate osteoclasts suggesting an important role for it in bone resorption. Mouse CCL9/10 is 75 % amino acid identical to rat CCL9/10. |
Mouse CCL9/MIP-1 gamma ELISA Kit PicoKine® |
|
EK1225 |
BosterBio |
96 wells |
EUR 499 |
|
|
|
Description: Mouse CCL9/MIP-1 gamma ELISA Kit PicoKine® (96 Tests). Quantitate Mouse Ccl9 in cell culture supernatants, cell lysates, serum and plasma (heparin, EDTA). Sensitivity: 1pg/ml. |
Mouse CCL9/Mip 1 Gamma PicoKine Fast ELISA Kit |
|
MBS1752764-5x96StripWells |
MyBiosource |
5x96-Strip-Wells |
EUR 2755 |
Mouse CCL9/Mip 1 Gamma PicoKine Fast ELISA Kit |
|
MBS1752764-96StripWells |
MyBiosource |
96-Strip-Wells |
EUR 600 |
Recombinant Mouse Ccl9/MIP-1 gamma Protein, No Tag |
|
E40MOP2097 |
EnoGene |
20ug |
EUR 495 |
Mouse MIP-1 Gamma (CCL9) Flow Cytometry Assay - Group 4 |
|
MX87121 |
Antigenix America |
96 Tests |
EUR 270 |
Mouse CCL9/Mip 1 Gamma PicoKine® Quick ELISA Kit |
|
FEK1225 |
BosterBio |
96 wells |
EUR 499 |
|
Description: Mouse CCL9/Mip 1 Gamma PicoKine® Quick ELISA Kit (90 minutes, 96 Tests). Quantitate Mouse Ccl9 in cell culture supernatants, cell lysates, serum and plasma (heparin, EDTA). Sensitivity: 1pg/ml. |
Mouse Macrophage Inflammatory Protein 1 Gamma-CCL9 ; MIP-1γ- |
|
QY-E21775 |
Qayee Biotechnology |
96T |
EUR 420 |
Recombinant Mouse Ccl9/MIP-01 gamma Protein, No Tag |
|
MOP2097 |
KMD Bioscience |
-
Ask for price
-
Ask for price
|
|
Mouse Ccl9 / MIP-1 Gamma (C-C motif chemokine 9) ELISA Kit |
|
MBS7612392-10x96StripWells |
MyBiosource |
10x96-Strip-Wells |
EUR 3900 |
Mouse Ccl9 / MIP-1 Gamma (C-C motif chemokine 9) ELISA Kit |
|
MBS7612392-48StripWells |
MyBiosource |
48-Strip-Wells |
EUR 340 |
Mouse Ccl9 / MIP-1 Gamma (C-C motif chemokine 9) ELISA Kit |
|
MBS7612392-5x96StripWells |
MyBiosource |
5x96-Strip-Wells |
EUR 2045 |
Mouse Ccl9 / MIP-1 Gamma (C-C motif chemokine 9) ELISA Kit |
|
MBS7612392-96StripWells |
MyBiosource |
96-Strip-Wells |
EUR 455 |
MIP-1 gamma Recombinant Protein |
|
40-340-0005mg |
ProSci |
0.005 mg |
EUR 311.1 |
|
Description: MIP-1 gamma is a CC chemokine found in murine blood and a wide variety of murine tissues, with no known human homolog. MIP-1 gamma signals through the CCR1 receptor. MIP-1 gamma chemoattracts neutrophils and also inhibits colony formation of bone marrow myeloid immature progenitors. MIP-1 gamma contains six cysteines including the four highly conserved cysteine residues present in CC chemokines. Recombinant murine MIP-1 gamma is an 11.6 kDa protein containing 101 amino acid residues. |
MIP-1 gamma Recombinant Protein |
|
40-340-002mg |
ProSci |
0.02 mg |
EUR 437.1 |
|
Description: MIP-1 gamma is a CC chemokine found in murine blood and a wide variety of murine tissues, with no known human homolog. MIP-1 gamma signals through the CCR1 receptor. MIP-1 gamma chemoattracts neutrophils and also inhibits colony formation of bone marrow myeloid immature progenitors. MIP-1 gamma contains six cysteines including the four highly conserved cysteine residues present in CC chemokines. Recombinant murine MIP-1 gamma is an 11.6 kDa protein containing 101 amino acid residues. |
MIP-1 Macrophage Inflammatory Protein-1 Gamma Mouse Recombinant Protein (CCL9) |
|
PROTP51670 |
BosterBio |
Regular: 20ug |
EUR 250 |
|
|
|
Description: MIP-1 gamma Mouse Recombinant produced in E. coli is a single, non-glycosylated, polypeptide chain containing 101 amino acids and having a molecular mass of 11.6 kDa. The MIP-1 gamma is purified by proprietary chromatographic techniques. |
Macrophage Inflammatory Protein 1 gamma, (MIP-1g) |
|
MBS628446-01mg |
MyBiosource |
0.1mg |
EUR 820 |
Macrophage Inflammatory Protein 1 gamma, (MIP-1g) |
|
MBS628446-5x01mg |
MyBiosource |
5x0.1mg |
EUR 3540 |
Mouse Anti Human Tubulin Gamma 1 |
|
MBS140528-0005mg |
MyBiosource |
0.005mg |
EUR 240 |
Mouse Anti Human Tubulin Gamma 1 |
|
MBS140528-002mg |
MyBiosource |
0.02mg |
EUR 310 |
Mouse Anti Human Tubulin Gamma 1 |
|
MBS140528-01mg |
MyBiosource |
0.1mg |
EUR 610 |
Mouse Anti Human Tubulin Gamma 1 |
|
MBS140528-5x01mg |
MyBiosource |
5x0.1mg |
EUR 2405 |
Recombinant Murine MIP-1 Gamma (CCL9/CCL10) Protein |
|
PROTP51670-1 |
BosterBio |
20ug |
EUR 380.4 |
|
Description: MIP-1γ is a CC chemokine found in murine blood and a wide variety of murine tissues, with no known human homolog. MIP-1γ signals through the CCR1 receptor. MIP-1γ chemoattracts neutrophils and also inhibits colony formation of bone marrow myeloid immature progenitors. MIP-1γ contains six cysteines including the four highly conserved cysteine residues present in CC chemokines. Recombinant murine MIP-1γ is an 11.6 kDa protein containing 101 amino acid residues. |
Macrophage Inflammatory Protein 1 gamma (MIP-1g) (AP) |
|
MBS6485912-01mL |
MyBiosource |
0.1mL |
EUR 1100 |
Macrophage Inflammatory Protein 1 gamma (MIP-1g) (AP) |
|
MBS6485912-5x01mL |
MyBiosource |
5x0.1mL |
EUR 4810 |
Macrophage Inflammatory Protein 1 gamma (MIP-1g) (PE) |
|
MBS6485922-01mL |
MyBiosource |
0.1mL |
EUR 1100 |
Macrophage Inflammatory Protein 1 gamma (MIP-1g) (PE) |
|
MBS6485922-5x01mL |
MyBiosource |
5x0.1mL |
EUR 4810 |
Macrophage Inflammatory Protein 1 gamma (MIP-1g) (APC) |
|
MBS6485913-01mL |
MyBiosource |
0.1mL |
EUR 1100 |
Macrophage Inflammatory Protein 1 gamma (MIP-1g) (APC) |
|
MBS6485913-5x01mL |
MyBiosource |
5x0.1mL |
EUR 4810 |
Macrophage Inflammatory Protein 1 gamma (MIP-1g) (HRP) |
|
MBS6485916-01mL |
MyBiosource |
0.1mL |
EUR 1100 |
Macrophage Inflammatory Protein 1 gamma (MIP-1g) (HRP) |
|
MBS6485916-5x01mL |
MyBiosource |
5x0.1mL |
EUR 4810 |
Macrophage Inflammatory Protein 1 gamma (MIP-1g) (FITC) |
|
MBS6485915-01mL |
MyBiosource |
0.1mL |
EUR 1100 |
Macrophage Inflammatory Protein 1 gamma (MIP-1g) (FITC) |
|
MBS6485915-5x01mL |
MyBiosource |
5x0.1mL |
EUR 4810 |
RABBIT ANTI MOUSE MIP-1 ALPHA |
|
MBS221275-01mg |
MyBiosource |
0.1mg |
EUR 635 |
RABBIT ANTI MOUSE MIP-1 ALPHA |
|
MBS221275-5x01mg |
MyBiosource |
5x0.1mg |
EUR 2695 |
MIP1 gamma protein (Mouse) |
|
MBS539594-002mg |
MyBiosource |
0.02mg |
EUR 465 |
MIP1 gamma protein (Mouse) |
|
MBS539594-5x002mg |
MyBiosource |
5x0.02mg |
EUR 1945 |
Macrophage Inflammatory Protein 1 gamma, Murine (MIP-1g) |
|
MBS635181-0005mg |
MyBiosource |
0.005mg |
EUR 340 |
Macrophage Inflammatory Protein 1 gamma, Murine (MIP-1g) |
|
MBS635181-002mg |
MyBiosource |
0.02mg |
EUR 490 |
Macrophage Inflammatory Protein 1 gamma, Murine (MIP-1g) |
|
MBS635181-5x002mg |
MyBiosource |
5x0.02mg |
EUR 2055 |
Macrophage Inflammatory Protein 1 gamma (MIP-1g) (Biotin) |
|
MBS6485914-01mL |
MyBiosource |
0.1mL |
EUR 1100 |
Macrophage Inflammatory Protein 1 gamma (MIP-1g) (Biotin) |
|
MBS6485914-5x01mL |
MyBiosource |
5x0.1mL |
EUR 4810 |
Macrophage Inflammatory Protein 1 gamma, Murine (MIP-1g) |
|
MBS629092-005mg |
MyBiosource |
0.05mg |
EUR 420 |
Macrophage Inflammatory Protein 1 gamma, Murine (MIP-1g) |
|
MBS629092-01mg |
MyBiosource |
0.1mg |
EUR 525 |
Macrophage Inflammatory Protein 1 gamma, Murine (MIP-1g) |
|
MBS629092-5x01mg |
MyBiosource |
5x0.1mg |
EUR 2210 |
Goat anti Mouse IgG (gamma) |
|
MBS315382-2mg |
MyBiosource |
2mg |
EUR 290 |
Goat anti Mouse IgG (gamma) |
|
MBS315382-5x2mg |
MyBiosource |
5x2mg |
EUR 1135 |
Mouse Monoclonal anti-human PLC gamma -1 |
|
hAP-0869 |
Angio Proteomie |
50ug |
EUR 400 |
Mouse anti Human IFN Gamma |
|
MBS226158-01mg |
MyBiosource |
0.1mg |
EUR 355 |
Mouse anti Human IFN Gamma |
|
MBS226158-5x01mg |
MyBiosource |
5x0.1mg |
EUR 1425 |
Mouse Anti-Human MIP-1 alpha |
|
MBS690908-05mg |
MyBiosource |
0.5mg |
EUR 525 |
Mouse Anti-Human MIP-1 alpha |
|
MBS690908-5x05mg |
MyBiosource |
5x0.5mg |
EUR 2080 |
Anti-PPAR gamma Mouse mAb |
|
MBS8533049-01mL |
MyBiosource |
0.1mL |
EUR 305 |
Anti-PPAR gamma Mouse mAb |
|
MBS8533049-01mLAF405L |
MyBiosource |
0.1mL(AF405L) |
EUR 565 |
Anti-PPAR gamma Mouse mAb |
|
MBS8533049-01mLAF405S |
MyBiosource |
0.1mL(AF405S) |
EUR 565 |
Anti-PPAR gamma Mouse mAb |
|
MBS8533049-01mLAF610 |
MyBiosource |
0.1mL(AF610) |
EUR 565 |
Anti-PPAR gamma Mouse mAb |
|
MBS8533049-01mLAF635 |
MyBiosource |
0.1mL(AF635) |
EUR 565 |
RAT ANTI MOUSE INTERFERON GAMMA |
|
MBS212196-025mg |
MyBiosource |
0.25mg |
EUR 500 |
RAT ANTI MOUSE INTERFERON GAMMA |
|
MBS212196-5x025mg |
MyBiosource |
5x0.25mg |
EUR 2070 |
Mouse Anti-Human IgG gamma |
|
BS21065 |
Bioworld Biotech |
100ul |
EUR 30 |
|
|
|
Description: E, WB, IH |
MOUSE ANTI HUMAN ACTIN GAMMA |
|
MBS224631-01mg |
MyBiosource |
0.1mg |
EUR 365 |
MOUSE ANTI HUMAN ACTIN GAMMA |
|
MBS224631-5x01mg |
MyBiosource |
5x0.1mg |
EUR 1465 |
Mouse anti-IFN gamma Antibody |
|
DL99450A-100ul |
DL Develop |
100 ul |
EUR 299 |
|
|
|
Description: Interferon gamma; IFN-gamma; Immune interferon |
Mouse anti-IFN gamma Antibody |
|
DL99450A-50ul |
DL Develop |
50 ul |
EUR 210 |
|
|
|
Description: Interferon gamma; IFN-gamma; Immune interferon |
Anti- Interferon Gamma (IFN-gamma) Mouse Antibody |
|
GWB-BB3356 |
GenWay Biotech |
0.1 mg |
Ask for price |
RABBIT ANTI MOUSE INTERFERON GAMMA |
|
MBS221259-01mg |
MyBiosource |
0.1mg |
EUR 635 |
RABBIT ANTI MOUSE INTERFERON GAMMA |
|
MBS221259-5x01mg |
MyBiosource |
5x0.1mg |
EUR 2695 |
Macrophage Inflammatory Protein 1 gamma, Murine (MIP-1g) (AP) |
|
MBS6485923-01mL |
MyBiosource |
0.1mL |
EUR 635 |
Macrophage Inflammatory Protein 1 gamma, Murine (MIP-1g) (AP) |
|
MBS6485923-5x01mL |
MyBiosource |
5x0.1mL |
EUR 2700 |
Macrophage Inflammatory Protein 1 gamma, Murine (MIP-1g) (PE) |
|
MBS6485933-01mL |
MyBiosource |
0.1mL |
EUR 635 |
Macrophage Inflammatory Protein 1 gamma, Murine (MIP-1g) (PE) |
|
MBS6485933-5x01mL |
MyBiosource |
5x0.1mL |
EUR 2700 |
MOUSE ANTI RAT INTERFERON GAMMA |
|
MBS212080-025mg |
MyBiosource |
0.25mg |
EUR 515 |
MOUSE ANTI RAT INTERFERON GAMMA |
|
MBS212080-5x025mg |
MyBiosource |
5x0.25mg |
EUR 2145 |
MOUSE ANTI RAT INTERFERON GAMMA |
|
MBS212081-01mg |
MyBiosource |
0.1mg |
EUR 365 |
MOUSE ANTI RAT INTERFERON GAMMA |
|
MBS212081-5x01mg |
MyBiosource |
5x0.1mg |
EUR 1465 |
Macrophage Inflammatory Protein 1 gamma, Murine (MIP-1g) (APC) |
|
MBS6485924-01mL |
MyBiosource |
0.1mL |
EUR 635 |
Macrophage Inflammatory Protein 1 gamma, Murine (MIP-1g) (APC) |
|
MBS6485924-5x01mL |
MyBiosource |
5x0.1mL |
EUR 2700 |
Macrophage Inflammatory Protein 1 gamma, Murine (MIP-1g) (HRP) |
|
MBS6485927-01mL |
MyBiosource |
0.1mL |
EUR 635 |
Macrophage Inflammatory Protein 1 gamma, Murine (MIP-1g) (HRP) |
|
MBS6485927-5x01mL |
MyBiosource |
5x0.1mL |
EUR 2700 |
Macrophage Inflammatory Protein 1 gamma (MIP-1g) (MaxLight 405) |
|
MBS6485917-01mL |
MyBiosource |
0.1mL |
EUR 1100 |
Macrophage Inflammatory Protein 1 gamma (MIP-1g) (MaxLight 405) |
|
MBS6485917-5x01mL |
MyBiosource |
5x0.1mL |
EUR 4810 |
Macrophage Inflammatory Protein 1 gamma (MIP-1g) (MaxLight 490) |
|
MBS6485918-01mL |
MyBiosource |
0.1mL |
EUR 1100 |
Macrophage Inflammatory Protein 1 gamma (MIP-1g) (MaxLight 490) |
|
MBS6485918-5x01mL |
MyBiosource |
5x0.1mL |
EUR 4810 |
Macrophage Inflammatory Protein 1 gamma (MIP-1g) (MaxLight 550) |
|
MBS6485919-01mL |
MyBiosource |
0.1mL |
EUR 1100 |
Macrophage Inflammatory Protein 1 gamma (MIP-1g) (MaxLight 550) |
|
MBS6485919-5x01mL |
MyBiosource |
5x0.1mL |
EUR 4810 |
Macrophage Inflammatory Protein 1 gamma (MIP-1g) (MaxLight 650) |
|
MBS6485920-01mL |
MyBiosource |
0.1mL |
EUR 1100 |
Macrophage Inflammatory Protein 1 gamma (MIP-1g) (MaxLight 650) |
|
MBS6485920-5x01mL |
MyBiosource |
5x0.1mL |
EUR 4810 |
Macrophage Inflammatory Protein 1 gamma (MIP-1g) (MaxLight 750) |
|
MBS6485921-01mL |
MyBiosource |
0.1mL |
EUR 1100 |
Macrophage Inflammatory Protein 1 gamma (MIP-1g) (MaxLight 750) |
|
MBS6485921-5x01mL |
MyBiosource |
5x0.1mL |
EUR 4810 |
Macrophage Inflammatory Protein 1 gamma, Murine (MIP-1g) (FITC) |
|
MBS6485926-01mL |
MyBiosource |
0.1mL |
EUR 635 |
Macrophage Inflammatory Protein 1 gamma, Murine (MIP-1g) (FITC) |
|
MBS6485926-5x01mL |
MyBiosource |
5x0.1mL |
EUR 2700 |
Macrophage Inflammatory Protein 1 gamma, Murine (MIP-1g) (Biotin) |
|
MBS6485925-01mL |
MyBiosource |
0.1mL |
EUR 635 |
Macrophage Inflammatory Protein 1 gamma, Murine (MIP-1g) (Biotin) |
|
MBS6485925-5x01mL |
MyBiosource |
5x0.1mL |
EUR 2700 |
Macrophage Inflammatory Protein 1 gamma, Murine (MIP-1g) (Biotin) |
|
MBS624246-0025mg |
MyBiosource |
0.025mg |
EUR 490 |
Macrophage Inflammatory Protein 1 gamma, Murine (MIP-1g) (Biotin) |
|
MBS624246-005mg |
MyBiosource |
0.05mg |
EUR 635 |
Macrophage Inflammatory Protein 1 gamma, Murine (MIP-1g) (Biotin) |
|
MBS624246-5x005mg |
MyBiosource |
5x0.05mg |
EUR 2700 |
MOUSE ANTI BOVINE INTERFERON GAMMA |
|
MBS224596-01mg |
MyBiosource |
0.1mg |
EUR 390 |
MOUSE ANTI BOVINE INTERFERON GAMMA |
|
MBS224596-5x01mg |
MyBiosource |
5x0.1mg |
EUR 1570 |
MOUSE ANTI BOVINE INTERFERON GAMMA |
|
MBS215222-05mg |
MyBiosource |
0.5mg |
EUR 715 |
MOUSE ANTI BOVINE INTERFERON GAMMA |
|
MBS215222-5x05mg |
MyBiosource |
5x0.5mg |
EUR 3035 |
MOUSE ANTI BOVINE INTERFERON GAMMA |
|
MBS215417-05mg |
MyBiosource |
0.5mg |
EUR 715 |
MOUSE ANTI BOVINE INTERFERON GAMMA |
|
MBS215417-5x05mg |
MyBiosource |
5x0.5mg |
EUR 3035 |
MOUSE ANTI BOVINE INTERFERON GAMMA |
|
MBS215513-05mg |
MyBiosource |
0.5mg |
EUR 715 |
MOUSE ANTI BOVINE INTERFERON GAMMA |
|
MBS215513-5x05mg |
MyBiosource |
5x0.5mg |
EUR 3035 |
Mouse Monoclonal anti-human Interferon gamma (IFN) gamma R1 |
|
hAP-0339 |
Angio Proteomie |
100ug |
EUR 250 |
Mouse anti actin gamma-cytoplasmic |
|
MBS570220-01mg |
MyBiosource |
0.1mg |
EUR 515 |
Mouse anti actin gamma-cytoplasmic |
|
MBS570220-5x01mg |
MyBiosource |
5x0.1mg |
EUR 2165 |
RABBIT ANTI MOUSE MIP-2 |
|
MBS221277-01mg |
MyBiosource |
0.1mg |
EUR 635 |
RABBIT ANTI MOUSE MIP-2 |
|
MBS221277-5x01mg |
MyBiosource |
5x0.1mg |
EUR 2695 |
MOUSE ANTI RAT TCR GAMMA/DELTA |
|
MBS212040-025mg |
MyBiosource |
0.25mg |
EUR 515 |
MOUSE ANTI RAT TCR GAMMA/DELTA |
|
MBS212040-5x025mg |
MyBiosource |
5x0.25mg |
EUR 2145 |
MOUSE ANTI RAT TCR GAMMA/DELTA |
|
MBS212041-01mg |
MyBiosource |
0.1mg |
EUR 365 |
MOUSE ANTI RAT TCR GAMMA/DELTA |
|
MBS212041-5x01mg |
MyBiosource |
5x0.1mg |
EUR 1465 |
MOUSE ANTI RAT TCR GAMMA/DELTA:RPE |
|
MBS213557-100Tests |
MyBiosource |
100Tests |
EUR 535 |
MOUSE ANTI RAT TCR GAMMA/DELTA:RPE |
|
MBS213557-5x100Tests |
MyBiosource |
5x100Tests |
EUR 2245 |
Anti-PP1C/PP1C gamma Mouse mAb |
|
E2200452 |
EnoGene |
100ul |
EUR 225 |
|
Description: Available in various conjugation types. |
Mouse Anti Human TCR Gamma/Delta |
|
MBS225833-01mg |
MyBiosource |
0.1mg |
EUR 400 |
Mouse Anti Human TCR Gamma/Delta |
|
MBS225833-5x01mg |
MyBiosource |
5x0.1mg |
EUR 1630 |
MOUSE ANTI CHICKEN TCR GAMMA/DELTA |
|
MBS224628-025mg |
MyBiosource |
0.25mg |
EUR 530 |
Adverse occasions: two small studies reported on mortality; one in every of these additionally reported on severe and different adversarial occasions, however pattern sizes had been too small for small variations to be detected. Therefore, low-quality proof means that the intervention might have little to no impact on mortality and different adversarial occasions. Health-related high quality of life: solely very low-quality proof from one examine is offered. We are unsure whether or not the intervention improves disease-specific high quality of lifetime of sufferers with bronchial asthma. Health-related outcomes: low-quality proof from eight studies means that the intervention might have little to no impact on bronchial asthma management, glycosylated haemoglobin (HbA1c) ranges, blood strain, low-density lipoprotein or whole levels of cholesterol, physique mass index or weight, or 10-year Framingham threat scores.
Low-quality proof from one examine means that the composite scores of threat components for diabetes mellitus might enhance barely with the intervention, however there’s uncertainty about results on ophthalmic medicines or intraocular strain. Psychosocial well being outcomes: no examine investigated psychosocial well being outcomes in a greater than anecdotal means. Health useful resource consumption: low-quality proof for grownup sufferers in three studies means that there could also be little to no impact of the intervention on completely different measures of well beingcare use. Patient-provider communication: very low-quality proof is offered from a single small examine, and we’re unsure whether or not the intervention improves communication measures, such because the variety of messages despatched.